-
公开(公告)号：US20140154685A1
公开(公告)日：2014-06-05
申请号：US13692477
申请日：2012-12-03
Inventor： Dominik M. DUELLI
IPC: C12Q1/68
CPC classification number: C12Q1/6806 , C12Q2525/207 , C12Q2527/125 , C12Q2527/137
Abstract: The present invention provides a kit for measuring the content of micro-RNA in a human blood sample including a blood collection tube containing at least 1 μg NaF and 0.8 μg KOx; and providing a set of instructions for collecting a human blood sample in the blood collection tube.
Abstract translation: 本发明提供了一种用于测量人血液样品中微RNA含量的试剂盒，其包括含有至少1μgNaF和0.8μgKOx的采血管; 以及提供用于在采血管中收集人血液样本的一组说明书。
-
72.发明公开公开(公告)号：US20230304041A1
公开(公告)日：2023-09-28
申请号：US18188932
申请日：2023-03-23
CPC classification number: C12N15/86 , C12Q1/701 , C12Q2600/136 , C12Q2600/158 , C12N2770/20043
Abstract: The present disclosure provides constructs and kits comprising SARS-CoV-2 (SARS2) replicons and methods for screening and/or evaluating anti-SARS2 drugs using the replicons.
-
公开(公告)号：US11732260B2
公开(公告)日：2023-08-22
申请号：US16977649
申请日：2019-03-01
Inventor： Frank Rigo , Michelle L. Hastings
IPC: C07H21/04 , C12N15/113
CPC classification number: C12N15/113 , C12N2310/11 , C12N2310/315 , C12N2310/32 , C12N2310/3231 , C12N2310/3233 , C12N2310/346 , C12N2320/33
Abstract: Certain embodiments disclosed herein are directed to compounds and methods for modulating APP expression. In certain embodiments, modulating the splicing of amyloid precursor protein (APP) reduces amyloid β (Aβ) production.
-
公开(公告)号：US11559231B2
公开(公告)日：2023-01-24
申请号：US16414951
申请日：2019-05-17
Inventor： Joanna Dabrowska
Abstract: A method and system is provided for determining a discrimination index in a subject that may be suffering from or at risk for a stress-induced psychiatric disorder. The discrimination index may be equal to a ratio of a subject's cued fear response and non-cued fear response measured during a fear-potentiated startle (FPS) paradigm. Such a value may allow a physician or researcher to quantify how well a subject discriminates between signaled (cued) fear and un-signaled (non-cued) fear, which may be a biomarker for psychiatric disorders like post-traumatic stress disorder, panic disorder, phobias, and/or generalized anxiety disorder. The determined discrimination index may provide a standardized way of diagnosing and evaluating mental illnesses, more uniform treatment of patients, and/or more precise monitoring and evaluation of treatment efficacy.
-
公开(公告)号：US20220280545A1
公开(公告)日：2022-09-08
申请号：US17274981
申请日：2019-09-10
Inventor： Michelle L. Hastings , Frank Rigo
IPC: A61K31/712 , A61K31/7125 , A61K31/713 , A61K47/02
Abstract: Provided are compounds, methods, and pharmaceutical compositions for modulating the expression of CLN3 RNA in a cell or animal, and in certain instances modulating the expression of CLN3 protein in a cell or animal Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such N symptoms and hallmarks include poor motor function, seizures, vision loss, poor cognitive function, psychiatric problems, accumulation of autofluorescent ceroid lipopigment, brain tissue dysfunction or cell death, accumulation of mitochondrial ATP synthase subunit C, accumulation of lipofuscin, or astrocyte activation in brain tissue.
-
Patent Agency Ranking
公开(公告)号：US20210393621A1
公开(公告)日：2021-12-23
申请号：US17288822
申请日：2019-10-25
Applicant: The Research Foundation for The State University of new York , Rosalind Franklin University of Medicine and Science , Board of Trustees of Michigan State University
Inventor： Christopher Roy Bishop , Anthony West , Fredric Manfresson
IPC: A61K31/496 , A61K31/198 , A61K31/4545 , A61K45/06 , A61K31/13 , A61K9/00
Abstract: A method of treating and attenuating L-DOPA-induced dyskinesia, comprising administering an effective dose of at least one pharmacological agent, e.g., vilazodone, having serotonin-specific reuptake inhibition (SSRI) and serotonin receptor 1A (5-HT1AR) partial agonism activity, in conjunction with L-DOPA. Other agents, such as an L-DOPA decarboxylase inhibitor, e.g., carbidopa, or other adjunct treatments may also be provided.
-
公开(公告)号：US20210346372A1
公开(公告)日：2021-11-11
申请号：US17240969
申请日：2021-04-26
Applicant: The Research Foundation for The State University of new York , Rosalind Franklin University of Medicine and Science , Board of Trustees of Michigan State University
Inventor： Christopher Roy Bishop , Anthony West , Fredric Manfresson
IPC: A61K31/496 , A61K31/198 , A61K31/495 , A61K31/05 , A61K31/55 , A61P25/16
Abstract: A method of treating and attenuating L-DOPA-induced dyskinesia, comprising administering an effective dose of at least one pharmacological agent, e.g., vilazodone, having serotonin-specific reuptake inhibition (SSRI) and serotonin receptor 1A (5-HT1AR) partial agonism activity, in conjunction with L-DOPA. Other agents, such as an L-DOPA decarboxylase inhibitor, e.g., carbidopa, or other adjunct treatments may also be provided.
-
公开(公告)号：US11116785B2
公开(公告)日：2021-09-14
申请号：US16730517
申请日：2019-12-30
Inventor： Michelle L. Hastings
IPC: A61K31/712 , C12N15/113
Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.
-
公开(公告)号：US20210040480A1
公开(公告)日：2021-02-11
申请号：US16977649
申请日：2019-03-01
Inventor： Frank Rigo , Michelle Hastings
IPC: C12N15/113
Abstract: Certain embodiments disclosed herein are directed to compounds and methods for modulating APP expression. In certain embodiments, modulating the splicing of amyloid precursor protein (APP) reduces amyloid β (Aβ) production.
-
公开(公告)号：US20180170897A1
公开(公告)日：2018-06-21
申请号：US15735840
申请日：2016-06-10
Applicant: STC.UNM , ROSALIND FRANKLIN UNIVERSITY
Inventor： Tudor I. Oprea , Cristian George Bologa , Oleg Ursu , Jun-Yong Choe , Cristina Iancu
IPC: C07D317/66 , A61K31/36 , A61K45/06 , C40B30/02 , A23L33/125
Abstract: The present invention relates to compounds which have been discovered to be potent ligands (inhibitors) of human GLUT5 (glucose transporter type 5), a facilitative glucose transporter that transports fructose, and their use as ligands assays which can uncover additional ligands of GLUT5, having the potential for being used as drugs. In addition, the present invention is directed to compounds, chemical compositions and methods for treating disease states and conditions which are mediated through GLUT5, including such disease states and conditions as GLUT5 deficiency syndrome, diabetes (type I and II), cancer, metabolic diseases including metabolic syndrome and fatty liver disease, among others.
-
-
-
-
-
-
-
-
-
Search Results
140
records
(took 0.031 seconds)
